脓毒症的分子表型识别:两项前瞻性观察队列分析及两项随机对照试验的二次分析
本研究利用VALID(N=1140)和EARLI(N=818)两个前瞻性脓毒症队列的血浆生物标志物与临床数据进行潜在类别分析,独立识别出两类别模型最优(p<0·0001)。VALID中炎症低下型804例(70·5%)、炎症高型336例(29·5%);EARLI中分别为530例(64·8%)和288例(35·2%)。炎症高型血浆促炎细胞因子更高、升压药使用更多、菌血症更多、蛋白C更低、死亡率更高(均p<0·0001)。分类模型显示脓毒症表型与既往ARDS表型高度一致(AUC 0·87–0·96)。在PROWESS-SHOCK试验中,活化蛋白C的疗效因表型而异(p=0·0043);在VASST试验中,升压药类型与表型无治疗交互作用(p=0·72)。作者认为分子表型可能代表超越综合征诊断的可治疗特征。
要点
- 脓毒症患者可独立分为炎症低下型与炎症高型两类别,VALID中分别占70·5%与29·5%,EARLI中占64·8%与35·2%(两类别模型拟合优度p<0·0001)。
- 炎症高型较炎症低下型血浆促炎细胞因子更高、升压药使用更多、菌血症更多、蛋白C更低、死亡率更高(均p<0·0001)。
- 脓毒症表型与既往ARDS表型高度一致,分类模型AUC 0·87–0·96(因模型而异)。
- PROWESS-SHOCK试验中活化蛋白C的治疗反应因表型不同而异(p=0·0043)。
- VASST试验中表型比例与其他队列相似,但升压药类型与表型无治疗交互作用(p=0·72)。
适用人群与场景
- 两个前瞻性脓毒症队列:VALID研究(N=1140)和EARLI研究(N=818)的危重症成人脓毒症患者。
- 两项随机对照试验的二次分析人群:PROWESS-SHOCK试验(N=1680)和VASST试验的脓毒症患者。
诊断标准与关键阈值
- 采用潜在类别分析基于临床数据和血浆生物标志物识别表型,两类别模型在VALID和EARLI中均最优(p<0·0001)。
- 使用经训练用于分类ARDS表型的验证模型评估脓毒症与ARDS表型的一致性,AUC 0·87–0·96(因模型而异)。
红旗征与不能漏的情况
- 炎症高型表型:血浆促炎细胞因子更高、升压药使用更多、菌血症更多、蛋白C更低、死亡率更高(均p<0·0001)。
研究设计与关键结果
- 研究类型:两项前瞻性观察队列(VALID、EARLI)的潜在类别分析,以及两项随机对照试验(PROWESS-SHOCK、VASST)的二次分析。
- VALID队列N=1140:炎症低下型804例(70·5%),炎症高型336例(29·5%);EARLI队列N=818:炎症低下型530例(64·8%),炎症高型288例(35·2%)。
- 炎症高型较炎症低下型血浆促炎细胞因子更高、升压药使用更多、菌血症更多、蛋白C更低、死亡率更高(均p<0·0001)。
- 脓毒症表型与既往ARDS表型高度一致,AUC 0·87–0·96(因模型而异);排除脓毒症合并ARDS的参与者后结果相似。
- PROWESS-SHOCK试验N=1680:炎症低下型1142例(68·0%),炎症高型538例(32·0%);对活化蛋白C的治疗反应因表型而异(p=0·0043)。
- VASST试验:表型比例与其他队列相似,但未观察到升压药类型与表型的治疗交互作用(p=0·72)。
证据类型、等级与局限
- 证据类型:前瞻性观察队列分析及随机对照试验二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,既往在ARDS中识别的分子表型也可在多个脓毒症队列中识别,且对活化蛋白C反应不同。
- 作者认为,分子表型可能代表超越患者综合征诊断的危重症可治疗特征。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In sepsis and acute respiratory distress syndrome (ARDS), heterogeneity has contributed to difficulty identifying effective pharmacotherapies. In ARDS, two molecular phenotypes (hypoinflammatory and hyperinflammatory) have consistently been identified, with divergent outcomes and treatment responses. In this study, we sought to derive molecular phenotypes in critically ill adults with sepsis, determine their overlap with previous ARDS phenotypes, and evaluate whether they respond differently to treatment in completed sepsis trials.
METHODS: We used clinical data and plasma biomarkers from two prospective sepsis cohorts, the Validating Acute Lung Injury biomarkers for Diagnosis (VALID) study (N=1140) and the Early Assessment of Renal and Lung Injury (EARLI) study (N=818), in latent class analysis (LCA) to identify the optimal number of classes in each cohort independently. We used validated models trained to classify ARDS phenotypes to evaluate concordance of sepsis and ARDS phenotypes. We applied these models retrospectively to the previously published Prospective Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis and Septic Shock (PROWESS-SHOCK) trial and Vasopressin and Septic Shock Trial (VASST) to assign phenotypes and evaluate heterogeneity of treatment effect.
FINDINGS: A two-class model best fit both VALID and EARLI (p<0·0001). In VALID, 804 (70·5%) of the 1140 patients were classified as hypoinflammatory and 336 (29·5%) as hyperinflammatory; in EARLI, 530 (64·8%) of 818 were hypoinflammatory and 288 (35·2%) hyperinflammatory. We observed higher plasma pro-inflammatory cytokines, more vasopressor use, more bacteraemia, lower protein C, and higher mortality in the hyperinflammatory than in the hypoinflammatory phenotype (p<0·0001 for all). Classifier models indicated strong concordance between sepsis phenotypes and previously identified ARDS phenotypes (area under the curve 0·87-0·96, depending on the model). Findings were similar excluding participants with both sepsis and ARDS. In PROWESS-SHOCK, 1142 (68·0%) of 1680 patients had the hypoinflammatory phenotype and 538 (32·0%) had the hyperinflammatory phenotype, and response to activated protein C differed by phenotype (p=0·0043). In VASST, phenotype proportions were similar to other cohorts; however, no treatment interaction with the type of vasopressor was observed (p=0·72).
INTERPRETATION: Molecular phenotypes previously identified in ARDS are also identifiable in multiple sepsis cohorts and respond differently to activated protein C. Molecular phenotypes could represent a treatable trait in critical illness beyond the patient's syndromic diagnosis.
FUNDING: US National Institutes of Health.
参考来源
- Sinha P, Kerchberger VE, Willmore A, et al. Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials. Lancet Respir Med. 2023. PMID: 37633303. doi:10.1016/S2213-2600(23)00237-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。